clinical trial · NCT04085523
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
AchondroplasiaTransCon CNPPlacebo for TransCon CNP
brief summary
The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
started
Jun 24, 2020
primary completion
Sep 27, 2022
completion
Oct 1, 2024
last updated
May 22, 2025
official title
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol